Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Baxter
Johnson and Johnson
Harvard Business School
Mallinckrodt

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

NEUTREXIN Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Neutrexin patents expire, and what generic alternatives are available?

Neutrexin is a drug marketed by Medimmune Oncology and is included in one NDA.

The generic ingredient in NEUTREXIN is trimetrexate glucuronate. There is one drug master file entry for this compound. Additional details are available on the trimetrexate glucuronate profile page.

Summary for NEUTREXIN
US Patents:0
Applicants:1
NDAs:1
Clinical Trials: 4
Formulation / Manufacturing:see details
DailyMed Link:NEUTREXIN at DailyMed
Drug patent expirations by year for NEUTREXIN
Recent Clinical Trials for NEUTREXIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Grupo Oncologico Cooperativo del SurPhase 2
U.S. BioscienceN/A

See all NEUTREXIN clinical trials

US Patents and Regulatory Information for NEUTREXIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-001 Dec 17, 1993 DISCN No No   Start Trial   Start Trial   Start Trial
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-002 Jul 31, 1998 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for NEUTREXIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-001 Dec 17, 1993   Start Trial   Start Trial
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-002 Jul 31, 1998   Start Trial   Start Trial
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-001 Dec 17, 1993   Start Trial   Start Trial
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-001 Dec 17, 1993   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Baxter
Medtronic
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.